文献速递认知障碍与痴呆

中年血浆淀粉样蛋白β水平与晚年认知障碍的关联:ARIC神经认知研究

Association of Midlife Plasma Amyloid-β Levels With Cognitive Impairment in Late Life: The ARIC Neurocognitive Study.
PubMed 文献 · Neurology · 2021-08-04

该研究基于ARIC队列中2284名参与者的回顾性数据,检测中年和晚年血浆Aβ42、Aβ40及Aβ42:Aβ40比值,分析其与晚年轻度认知障碍(MCI)和痴呆风险的关系。结果显示,中年Aβ42:Aβ40比值每翻倍与MCI/痴呆风险降低37%相关,但仅至中位数附近;中年Aβ42每升高1个标准差与风险降低13%相关,而Aβ40每升高1个标准差与风险升高15%相关。晚年测量关联类似但统计稍弱,中年至晚年的变化与认知结局无关。

要点

  • 中年血浆Aβ42:Aβ40比值翻倍与MCI/痴呆风险降低37%相关,但仅至中位数附近。
  • 中年Aβ42每升高1个标准差(10 pg/mL)与MCI/痴呆风险降低13%相关。
  • 中年Aβ40每升高1个标准差(67 pg/mL)与MCI/痴呆风险升高15%相关。

核心结论

  • 中年血浆Aβ测量可能作为预测未来认知障碍风险的血液生物标志物。

研究设计与样本

  • 回顾性测量ARIC队列子样本2284名参与者的血浆Aβ42和Aβ40,随访2011-2019年认知结局。

主要发现

  • 中年Aβ42:Aβ40每翻倍与MCI/痴呆风险降低37%相关(RRR 0.63,95%CI 0.46-0.87),仅至中位数附近(样条模型阈值0.20)。
  • 中年Aβ42每升高1-SD(10 pg/mL)与MCI/痴呆风险降低13%相关(RRR 0.87,95%CI 0.77-0.98)。
  • 中年Aβ40每升高1-SD(67 pg/mL)与MCI/痴呆风险升高15%相关(RRR 1.15,95%CI 1.01-1.29)。
  • 晚年血浆Aβ预测的关联类似但统计稍弱,中年至晚年Aβ变化与认知结局无关。

临床怎么用

  • 中年血浆Aβ42:Aβ40、Aβ42和Aβ40水平可能有助于识别晚年认知障碍高风险个体。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: To evaluate the association between midlife plasma amyloid-β (Aβ1-42, Aβ1-40, Aβ42:Aβ40) and risk of mild cognitive impairment (MCI) and dementia. METHODS: Plasma Aβ42 and Aβ40 were retrospectively measured with a fluorometric bead-based immunoassay in a subsample of the Atherosclerosis Risk in Communities cohort study. We investigated the relationship of plasma Aβ42, Aβ40, and Aβ42:Aβ40 ratio measured in midlife and late life and the change from midlife to late life to risk of MCI, dementia, and combined MCI/dementia outcomes in late life (from 2011-2019). We used multinomial logistic regressions estimating relative risk ratios (RRRs) of these cognitive outcomes vs cognitively normal adjusted for age, sex, education, site-race, APOE, hypertension, diabetes, and body mass index. RESULTS: A total of 2,284 participants were included (midlife mean age 59.2 ± 5.2, 57% female, 22% Black). Each doubling of midlife Aβ42:Aβ40 was associated with 37% lower risk of MCI/dementia (RRR 0.63, 95% confidence interval [CI] 0.46-0.87), but only up to approximately the median (spline model threshold 0.20). Every 1-SD increase in plasma Aβ42 (10 pg/mL) was associated with 13% lower risk of MCI/dementia (RRR 0.87, 95% CI 0.77-0.98), whereas every 1-SD increase in plasma Aβ40 (67 pg/mL) was associated with 15% higher risk of MCI/dementia (RRR 1.15, 95% CI 1.01-1.29). Associations were comparable but slightly weaker statistically when models were repeated using late-life plasma Aβ predictors. Aβ42 and Aβ40 increased from midlife to late life, but changes were not associated with cognitive outcomes. DISCUSSION: Midlife measurement of plasma Aβ may have utility as a blood-based biomarker indicative of risk for future cognitive impairment.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Sullivan KJ, Blackshear C, Simino J, et al. Association of Midlife Plasma Amyloid-β Levels With Cognitive Impairment in Late Life: The ARIC Neurocognitive Study. Neurology. 2021. PMID: 34349010. doi:10.1212/WNL.0000000000012482

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。